← Search & browse all drugs
BLOOD AND BLOOD FORMING ORGANS › ANTIANEMIC PREPARATIONS › OTHER ANTIANEMIC PREPARATIONS › Other antianemic preparations
methoxy polyethylene glycol-epoetin beta
B03XA03
Forms & Strengths
- Solution for Injection: 100 mcg/mL
- Solution for Injection: 200 mcg/mL
- Solution for Injection: 500 mcg/mL
- Solution for Injection: 1000 mcg/mL
- Pre-filled Syringe: 100 mcg/mL
- Pre-filled Syringe: 200 mcg/mL
- Pre-filled Syringe: 500 mcg/mL
- Pre-filled Syringe: 1000 mcg/mL
Adult Dosing
- Chronic kidney disease: 50-100 mcg/kg/week IV/SC
- Anemia in cancer patients: 50-150 mcg/kg/week IV/SC
- Surgery: 100-300 mcg/kg/day IV/SC
Pediatric Dosing
- Chronic kidney disease: 50 mcg/kg/week IV/SC (4-18 years old)
Indications
- Treatment of anemia associated with chronic kidney disease
- Treatment of anemia in patients with non-myeloid malignancies receiving chemotherapy
- Reduction of allogeneic blood transfusions in patients undergoing major elective surgery
Mechanism of Action
- Stimulates erythropoiesis by binding to erythropoietin receptors
- Increases red blood cell production
Contraindications
- Hypersensitivity to methoxy polyethylene glycol-epoetin beta or any of its excipients
- Pure red cell aplasia
Adverse Reactions
- Hypertension
- Headache
- Nausea and vomiting
- Fatigue
- Influenza-like illness
- Thrombocytosis
- Increased risk of thromboembolic events
Drug Interactions
- Reduced efficacy with heparin
- Potential increased risk of thrombosis with estrogen-containing medications
Curated Content: Needs Vetting Before Put to Clinical Use